The Europe Patient Access Solutions Market would witness market growth of 8.7% CAGR during the forecast period (2022-2028).
Specialized advocacy organizations aim to ensure patient access to certain medicines and clinical care in addition to the high-level campaign for universal healthcare access. For instance, a nationwide network of doctors called the Alliance for Patient Access (APA) promotes conferences, working groups for physicians, and health policy initiatives. It also disseminates educational materials and arranges meetings with health policymakers. The Issues website of the APA lists important subjects of interest, such as certain therapeutic fields, policy issues, and other activities.
Access by patients to investigational or unapproved medicines is a major subject of lobbying efforts. Drugs that are experimental or have not yet received FDA approval may be the only option for treating severely ill patients who may not live long enough to wait for the approval of new therapies. Several states have enacted "right-to-try" laws that permit terminally ill people to obtain experimental medicines or devices as a result of patient demand and advocacy activities. The FDA has also widened its rules for compassionate use, experimental pharmaceuticals, and off-label applications of medicines that have already been approved.
The EU Council and Parliament's "Horizon Europe" program, which was adopted in full in April 2021 and retrospectively came into effect on January 1, 2021, also emphasizes R&D and innovation in the areas of health and the health sector. Initiatives focus on fighting cancer, smart health, aging, and digital care approaches. However, the German healthcare system is complex and sluggish to adopt new trends due to its decentralized and self-governing structure. Officials from the German health ministry are committed to bringing the German health system into the digital era and have changed the legal framework with several regulations. The digitalization of the health sector and the use of the Hospital Future Act's finances accelerate the growth of the patient access solution market.
The Germany market dominated the Europe Patient Access Solutions Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $219.3 million by 2028. The UK market is showcasing a CAGR of 7.8% during (2022 - 2028). Additionally, The France market would witness a CAGR of 9.5% during (2022 - 2028).
Based on Offering, the market is segmented into Services and Software. Based on Software Type, the market is segmented into Eligibility Verification Software, Medical Necessity Management Software, Precertification & Authorization Software, Claims Denial & Appeal Management, Payment Estimation Software and Claims Payment Assessment, Processing Software & Others. Based on Deployment Mode, the market is segmented into Web & Cloud-based Solutions and On-premises. Based on End User, the market is segmented into Healthcare Providers, HCIT Outsourcing Companies and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Patient Access Solutions Market will Hit $3.3 Billion by 2028, at a CAGR of 9.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include UnitedHealth Group, Inc. (Optum, Inc.), Cognizant Technology Solutions Corporation, McKesson Corporation, Oracle Corporation (Cerner Corporation), Experian PLC, 3M Company, Epic Systems Corporation, AllScripts Healthcare Solutions, Inc., F. Hoffmann-La Roche Ltd. (Genentech, Inc.), and Tenet Healthcare Corporation (Conifer Health Solutions, LLC).
By Offering
By Deployment Mode
By End User
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 